耐酸化学动态DNA微机用于在炎症性肠病中提供益生菌
Zinan Zhao1, Yao Xu1, Yong Hu2
1Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University, Shanghai, 201804, P. R. China.
Nature communications
|April 22, 2025
概括
新的DNA微囊为炎症性肠病 (IBD) 提供了改善的口服益生菌输送. 这些微动力保护益生菌并准炎症结肠,增强治疗潜力.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 胃肠病学 胃肠病学
背景情况:
- 合成聚合物微囊用于口服益生菌的输送,但缺乏抗酸性,结肠特异性和受控释放.
- 现有的系统无法在恶劣的胃肠道环境中充分保护益生菌,并准炎症的结肠部位.
研究的目的:
- 开发先进的DNA微囊作为微动力,用于增强口服益生菌的输送.
- 改善益生菌活力,实现炎性结肠特异性,并使炎性肠病 (IBD) 管理的控制释放成为可能.
主要方法:
- 通过氨酸甲基酸和富A/C的寡合体的光交联制造DNA微囊.
- 纳入氧化可分离的交叉连接剂和碳 (MnCO) 作为气体捐赠体.
- 利用可逆的A-动机和i-动机结构过渡来进行缩小-胀行为和向炎症结肠中反应性氧物种 (ROS) 的化学反应.
主要成果:
- DNA微囊显示了可逆的缩小-胀过渡,在整个胃肠道过渡过程中保持了益生菌的活力.
- 微囊对炎症结肠部位表现出化学作用,由MnCO反应与ROS升高所驱动.
- 氧化触发了微囊的分解,促进了受控的益生菌释放.
结论:
- 开发的DNA微囊系统显示出作为口服益生菌的先进输送工具的重大承诺.
- 这项技术为重新塑造肠道微生物群和管理炎症性肠病 (IBD) 提供了潜在的策略.
相关概念视频
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
96
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
96
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80


